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Abstract 
Gamma-hydroxybutyric acid (GHB) is a well-known illicit club and date-rape drug. Dried 
blood spot (DBS) sampling is a promising alternative for classical venous sampling in cases 
of (suspected) GHB intoxication since it allows rapid sampling, which is of interest for the 
extensively metabolized GHB. However, there is limited data if -and how- capillary DBS 
concentrations correlate with venous concentrations. We conducted a comparative study in 50 
patients with suspected GHB intoxication, to determine and to correlate GHB concentrations 
in venous DBS (vDBS) and capillary DBS (cDBS). This is the first study that evaluates in a 
large cohort the correlation between capillary and venous concentrations of an illicit drug in 
real-life samples. Of the 50 paired samples, 7 were excluded: the vDBS concentration was 
below the LLOQ of 2 g/mL in 3 cases and 4 samples were excluded after visual inspection 
of the DBS. Bland-Altman analysis revealed a mean % difference of -2.8% between cDBS 
and vDBS concentrations, with the zero value included in the 95% confidence interval of the 
mean difference in GHB concentration. A paired sample t-test confirmed this observation 
(p=0.17). Also the requirement for incurred sample reproducibility was fulfilled: for more 
than 2/3 of the samples the concentrations obtained in cDBS and those in vDBS were within 
20% of their mean. Since equivalent concentrations were observed in cDBS and vDBS, blood 














Gamma-hydroxybutyrate (GHB) and its precursor gamma-butyrolactone (GBL) are used as 
recreational drug and date-rape drug, particulary in a nightclub environment and in men 
having sex with men. There have been many cases of GHB intoxication, also in combination 
with other drugs of abuse.
[1-4] 
Toxicological interpretation of GHB concentrations in clinical 
and forensic samples is impeded by its endogenous presence. Furthermore, given the short 
half-life of GHB, rapid sampling is needed.
[5] 
Dried blood spot (DBS) sampling has been 
proposed as a possible alternative for classical venepuncture, offering several advantages, in 
particular rapid and easy collection of a representative sample and easy sample transfer and 
storage.
[6] 
A number of studies have provided a proof-of-concept of the potential to determine 
abused substances, including GHB, in DBS samples.
[7]
 However, these studies have generally 
not assessed the developed methodology in a large cohort of patients, comparing capillary 
samples with the gold standard of venous samples. In addition, in most reports a cross-
comparison between venous DBS (vDBS) and capillary DBS (cDBS) concentrations is 
lacking.
[7]
 Therefore, although DBS sampling is an interesting and promising alternative to 
classical venous sampling, it remains to be demonstrated if cDBS concentrations correlate 
with those in venous samples. While we previously demonstrated that GHB can be 
quantitatively determined in DBS of patients with a GHB/GBL intoxication and in narcoleptic 
patients taking the medication Xyrem
®
 (sodium oxybate, the sodium salt of GHB)
[8-10]
, the 
aim of this study was to compare GHB concentrations in vDBS and cDBS in a large cohort of 
patients with acute GHB intoxication. 
 
Materials and methods 
With the exception of the sodium fluoride/potassium oxalate (NaF-KOx) blood collection 
tubes (9 mL tubes with 100 mg sodium fluoride and 22.50 mg potassium oxalate obtained 
from Terumo UK Ltd), all materials were provided from previously published suppliers.
[8] 
Samples 
This study was approved by The UK National Research Ethics Service (Reference 
11/LO/0976). All patients presenting to the Emergency Department at St Thomas’ Hospital, 
London with either a clinical diagnosis or other indications of GHB/GBL intoxication were 
considered for inclusion. cDBS were generated by non-volumetric direct application of a 
blood drop from the fingertip onto Whatman filter paper following a fingerprick. vDBS were 
obtained by pipetting 25 µL of venous blood from the NaF-KOx blood tubes in which the 
venous samples were collected and stored. DBS were dried for at least 2 hours before storage 
at room temperature in zip-closure plastic bags with desiccant. Paired cDBS and venous 
whole blood samples were collected at the time of admission from 99 patients. As these 
patients were generally drowsy or agitated at presentation, informed consent was not possible 
prior to the collection of samples and therefore delayed consent was employed. Of the patients 
sampled, 50 provided delayed consent. The paired samples obtained from these 50 patients 
were used in this study. 
 Analytical procedures 
GHB concentrations in DBS were determined as described before, using a validated GC-MS-
based procedure.
[9]
 Briefly, 6-mm partial-spot punches were taken from the DBS. After 
adding the internal standard GHB-d6, the DBS punches were subjected to “on-spot 
derivatization” by direct application of a mixture of 50 µL trifluoroacetic acid anhydride and 
heptafluorobutanol (2:1) and heating for 10 min at 60°C. After evaporation under a gentle 
stream of nitrogen, the dried extract was re-dissolved in 100 µL ethylacetate and 1 µL was 
injected into an Agilent 6890 GC system coupled to a 5973 mass spectrometer. Of those DBS 
with a GHB concentration above 100 µg/mL, 10 µL of the final derivatized extract was 
diluted to 100 µL with ethyl acetate. The capillary column was a 30 m x 0.25 mm i.d. x 0.25 
µm Agilent HP-5MS column. The injection temperature was set at 250°C, and a splitless 
injection was performed with a purge time of 1.5 min. The initial column temperature was set 
at 60°C for 1.5 min, ramped at 10°C/min to 110°C, then raised by 50°C/min to 300°C, which 
was held for 2 min, resulting in a total analysis time of 12.3 min. High-purity helium was used 
as the carrier gas with a constant flow rate of 1.3 mL/min. The transfer line temperature and 
ion source temperature were set at 280 and 230°C, respectively. MS quadrupole temperature 
was set at 150°C and ionization energy of 70 eV was used. Quantification of GHB and GHB-
d6 was performed in the selected ion monitoring (SIM) mode using m/z 155, 183, 227 and 
242 for derivatized GHB and 161, 189, 231 and 245 for derivatized GHB-d6. 
 
Storage experiment 
To evaluate GHB stability in venous whole blood (collected in NaF-KOx tubes), we added 
two different concentrations (10 and 100 µg/mL) in whole blood and stored the samples at 
different temperatures (4°C and room temperature) for up to 2 weeks. At different time points, 
25-µL DBS were generated from this spiked blood, which were analyzed using the above-
mentioned DBS-based GC-MS method. 
Data analysis 
To evaluate the correlation between venous and capillary concentrations, we performed a 
paired sample t-test, using Excel, and Bland-Altman and Passing-Bablok analysis, using 
MedCalc
® 
(MedCalc software bvba, Ostend, Belgium). 
A p-value ≤ 0.05 was considered statistically significant. In the Bland-Altman plot, the 
differences between venous and capillary concentrations were plotted against the average of 
both measurements. Indicated in this plot are the mean difference between both 
concentrations and the limits of agreement (1.96 SD), along with the respective 95% 
confidence intervals. In the Passing-Bablok scatter plot diagram, capillary concentrations 
were plotted against venous concentrations. If the confidence interval of the slope includes 1, 
there is no proportional difference between both measurements. When the confidence interval 
of the intercept value includes 0, it can be concluded that there is no systematic difference 
between both methods.  
 Results and discussion 
Of the 50 paired samples, 7 were excluded: the vDBS concentration of 3 samples was below 
the LLOQ of 2 µg/mL, while 4 samples were excluded after visual inspection of the DBS (in 
3 cases cDBS samples were too small (< 6 mm diameter) and in one case vDBS had an 
irregular shape). cDBS concentrations of GHB ranged from 41 to 646 µg/mL, whereas vDBS 
concentrations ranged from 48 to 705 µg/mL. Clinically, all patients - apart from the 3 
patients with a vDBS concentration below LLOQ - had clinical symptoms consistent with 
acute GHB intoxication.  
In literature, a cut-off GHB concentration of 4-5 µg/mL in blood has been proposed to 
differentiate between endogenous and exogenous GHB.
[5,11-13]
 In our study, 43 patients were 
screened positive for GHB: both venous and capillary concentrations were well above these 
cut-off levels. In the 3 cases of our study that did not have symptoms of acute GHB 
intoxication, vDBS concentrations were below the limit. However, GHB intake is likely as 
clearly higher signals were detected than those found in GHB-naïve persons (see Figure 1). 
These cases presented to the hospital with clinical symptoms consistent with recent stimulant 
use or secondary to GHB withdrawal rather than acute intoxication. In all 3 cases, there was 
some evidence that GHB use may have taken place more than 5 hours before sampling (e.g. 
history of GHB abuse, declared GHB use,…). However, it was not possible to formally 
confirm GHB use in these patients, as urine samples were not routinely collected. As 
suggested by these 3 cases, rapid sampling is of utmost importance since GHB is metabolized 
rapidly, with a half-life of less than one hour, resulting in blood concentrations below 
proposed cut-off levels within a few hours after use.
[14,15]
 Shima and colleagues proposed 
lowering the cut-off to 1 g/mL in blood in cases where in-life blood specimens can be 
collected aseptically and stored at 4°C or lower before timely analysis.
[16]
 In legal cases, 
cDBS samples may provide the advantage that they may not only allow rapid sampling, but 
also stabilise the sample, allowing long-term storage at room temperature.
[9]
 
We performed Bland-Altman analysis to compare cDBS and vDBS concentrations. As can be 
seen in Figure 2a, we found a mean % difference of -2.8%, with the zero value included in the 
95% confidence interval of the mean difference in GHB concentration. From this, it can be 
concluded that there is no significant difference between cDBS and vDBS concentrations. A 
paired sample t-test confirmed this conclusion (p=0.17). We also applied the European 
Medicine Agency (EMA) guideline for incurred sample reanalysis in bioanalytical method 
validation.
[17]
 These state that the concentration obtained for the initial analysis and the 
concentration obtained by reanalysis should be within 20% of their mean for at least 67% of 
the repeats. Although this requirement actually concerns reanalysis of the same samples, this 
condition was still fulfilled when analyzing different (cDBS versus vDBS) samples: in 72% of 
cases the concentrations obtained in cDBS and those in vDBS were within 20% of the mean 
GHB concentrations obtained with the 2 methods. As can be seen in Figure 2b, a Passing-
Bablok scatter plot also demonstrated a good overall correlation between cDBS and vDBS 
GHB concentrations, although 1 was just not included in the 95% confidence interval of the 
slope. 
In addition to performing a pairwise comparison between cDBS and vDBS, we also 
performed reanalysis of both cDBS (n=29) and vDBS (n=28). Again, the EMA requirement 
for incurred sample reanalysis was fulfilled: we found that for more than two-thirds (i.e. 70%) 
of the samples the initial concentration and the concentration obtained by reanalysis, were 
within 20% of the mean of the first and repeat measurement.  
It should be noted that, while cDBS and venous blood were sampled at almost the same time 
point, in some cases, there was a delay of several days before vDBS were prepared from the 
venous blood. To exclude that this may have an effect on our results, we evaluated GHB 
stability in spiked venous whole blood collected in NaF-KOx tubes that were stored for up to 
two weeks at 4°C and at room temperature before DBS preparation. The bias from nominal 
concentrations (10 or 100 g/mL) did not exceed 11%. This suggests that no substantial 
alteration takes place in GHB concentration if venous blood, collected in NaF-Kox tubes, is 
stored under these conditions. Although this finding is consistent with previously published 
data
[18-20]
, it should be noted that in incurred (real-life) samples a contribution from e.g. 
hydrolysis of GHB glucuronide might not be excluded. However, such contribution is 





DBS sampling is a promising alternative for classical venous sampling in cases of (suspected) 
GHB intoxication: the DBS sampling technique allows rapid sampling -which is of interest 
for the extensively metabolized GHB- and DBS are also easier to store and transport than 
venous samples. The study reported here is the largest comparative study to date evaluating 
capillary and venous concentrations of an illicit drug. In a large cohort of patients with acute 
GHB intoxication we observed equivalent GHB concentrations and an excellent correlation 
between cDBS and vDBS. In conclusion, blood obtained by fingerprick is a valid alternative 
for venous blood for GHB determination. 
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 Figure legends 
Figure 1: Overlay of representative chromatograms obtained by analyzing (a) vDBS of a 
GHB-naïve person, (b) vDBS of a patient with assumed GHB intake (GHB concentration < 2 
µg/mL), (c) vDBS with a GHB concentration of 2 µg/mL (LLOQ), (d) vDBS of a GHB-
intoxicated person (GHB concentration of 48 µg/mL), using a DBS-based GC-MS method
[9]
.  
Figure 2: (a) Bland-Altman analysis of cDBS and vDBS, plotting the % differences between 
both GHB concentrations (y-axis) against the average of these results (x-axis). The mean 
difference and the limits of agreement (set to 1.96 SD) are also indicated with its 95% 
confidence interval. (b) Passing-Bablok regression analysis of cDBS and vDBS, plotting the 
concentrations in both matrices against each other. The solid line illustrates the regression 
line, the dashed lines indicate the confidence interval for the regression line and the dotted 
line corresponds to the identity line.  
 
 
